Adial Pharmaceuticals Receives Milestone Payment as Adovate Launches Phase 1 Trial for Novel Asthma Therapy
Adial Pharmaceuticals has received a six-figure milestone payment from Adovate following the initiation of a Phase 1 clinical trial for ADO-5030, a novel adenosine receptor antagonist targeting asthma.
Adial Pharmaceuticals' AD04 Shows Positive Pharmacokinetics for Alcohol Use Disorder Treatment
Adial Pharmaceuticals' AD04 demonstrated predictable bioavailability and dose proportionality in a recent pharmacokinetics study, AD04-103.
© Copyright 2025. All Rights Reserved by MedPath